FY2019 EHE Supplements

The UCSF-Gladstone Center for AIDS Research (CFAR) announces the availability of supplemental funding to address the “Ending the HIV Epidemic: A Plan for America” (EtHE) initiative (Webcast here: http://www.croiwebcasts.org/console/player/41036?mediaType=slideVideo&). The UCSF Center for AIDS Prevention Studies (CAPS) is also eligible to submit supplements for this opportunity. Each center (both CFAR and CAPS) is eligible to submit three applications, for a total of 6 applications. NIH requires that CFAR and CAPS coordinate the selection of projects to prevent overlap. Therefore, we will be conducting a joint internal competition to determine which applications will go forward for submission to the NIH.

Proposed projects should be for the purpose of planning EtHE activities with your collaborating partners. It is anticipated CDC, HRSA and IHS programs/projects targeted toward the EtHE initiative will be funded in FY20. The CFAR/CAPS planning projects are for FY19 to begin discussions with local partners around potential FY20 projects. These planning projects may include feasibility studies, especially if collaborations have already been established and are ongoing, with the possibility that successful projects would lead into expanded implementation science studies next year.

The key aspects of this funding opportunity are:

  • Applications may be submitted for up to one year with maximum funding per application of up to $100,000 Direct Costs (subcontract indirect costs are allowed and are not included in the Direct Costs limit)
  • Applications must include collaborating partners as described in the announcement
  • Projects must address one or more of the four key pillars: Diagnose, Treat, Protect, and Respond
  • Projects that are a continuation of previously funded CFAR/CAPS supplements or funded NIH applications that do not address new specific aims are not eligible for funding under this announcement
  • The earliest anticipated start date is July 08, 2019 but may be delayed due to administrative issues
  • No NIH-defined clinical trials are allowed. If an intervention is planned, the study must evaluate feasibility only.